Aktis Oncology Pursues $200 Million IPO On Promising Early Stage Studies (Pending:AKTS)
Aktis Oncology Pursues $200 Million IPO On Promising Early Stage Studies
Source link
Aktis Oncology Pursues $200 Million IPO On Promising Early Stage Studies
Source link
About 400KOz was mined from the Hawkins Hill area (NSW) in the 19th century. Current inferred JORC resource stands at 680Kt @ 6g/t Au for 130 KOz. During assaying gold recoveries have been shown to be around 98% of the gold. A scoping study was announced in the June 2006 quarterly. Mining would be by…
This article was written by Follow Michael James McDonald is a stock market forecaster, author and former Senior Vice President of Investments at what is now Morgan Stanley. He is a long-term advocate of the theory of contrary opinion and the measurement of investor sentiment when forecasting price direction.His first book, ” A Strategic Guide…
by Calculated Risk on 12/30/2025 02:00:00 PM From the Fed: Minutes of the Federal Open Market Committee, December 9–10, 2025. Excerpt: In their consideration of monetary policy at this meeting, participants noted that inflation had moved up since earlier in the year and remained somewhat elevated. Participants further noted that available indicators suggested that economic…
They say that “bull markets climb a wall of worry.” The idea is that you need investors to be pessimistic about the future to create a buying opportunity. As optimism gradually takes over, stocks steadily soar. The old adage has certainly been true during my career. The best time to buy stocks was when everyone…
By Lawrence G. McMillan The last of our indicators to turn fully bullish was the chart of $SPX itself. Sometimes that happens, where $SPX is lagging the indicators, but now it has caught up. The move to new all-time highs by the Index was confirmed with a two-day close. Now, there should be support at…
OptimizeRx (NASDAQ:OPRX – Get Free Report) released its quarterly earnings results on Thursday. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.03 by $0.17. OptimizeRx had a positive return on equity of 4.50% and a negative net margin of 9.42%.The business had revenue of $26.07 million during the quarter, compared…